NCT04403555

Brief Summary

Efficacy of Ivermectin in COVID-19 treatment

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
164

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jun 2020

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 23, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 27, 2020

Completed
5 days until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

August 2, 2021

Status Verified

July 1, 2021

Enrollment Period

5 months

First QC Date

May 23, 2020

Last Update Submit

July 29, 2021

Conditions

COVID

Outcome Measures

Primary Outcomes (1)

  • The number of patients with mortality

    Improvement of survival

    1 month

Secondary Outcomes (2)

  • Length of hospital stay

    1 month

  • The need for mechanical ventilation

    1 month

Study Arms (2)

Ivermectin

EXPERIMENTAL

Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days

Drug: Ivermectin

Standard of care

NO INTERVENTION

Standard of care treatment

Interventions

IvermectinDRUG

Ivermectin treatment

Also known as: iverzine, ivermectin
Ivermectin

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.

You may not qualify if:

  • Allergy or contraindication to the drugs used in the study.
  • Pregnant and lactating mothers.
  • Patients with cardiac problems.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sherief Abd-Elsalam

Tanta, Egypt

Location

MeSH Terms

Interventions

Ivermectin

Intervention Hierarchy (Ancestors)

MacrolidesPolyketidesLactonesOrganic Chemicals

Study Officials

  • sherief Abd-Elsalam, Ass. Prof.

    ass. Prof. Tropical Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass. Prof. Tropical Medicine

Study Record Dates

First Submitted

May 23, 2020

First Posted

May 27, 2020

Study Start

June 1, 2020

Primary Completion

October 31, 2020

Study Completion

December 1, 2020

Last Updated

August 2, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)